Form 4: Omeros Corp Grants 100,000 Stock Options to VP, General Counsel Peter B. Cancelmo

Omeros Corp has granted 100,000 stock options to Peter B. Cancelmo, VP and General Counsel, with an exercise price of $3.20 per share, vesting over 48 months.

Summary

• Peter B. Cancelmo, VP, General Counsel of Omeros Corp, was granted 100,000 stock options.
• The options have an exercise price of $3.20 per share.
• The options will vest in 48 equal monthly installments, beginning April 1, 2025.
• The options expire on June 30, 2035.
• Following this transaction, Peter B. Cancelmo beneficially owns 100,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term retention. It's a standard compensation practice, not indicative of extraordinary positive or negative news, hence a moderately positive score.

Positives

• The grant of 100,000 stock options to a key executive like the VP, General Counsel, aligns management's interests with shareholder value creation.
• The vesting schedule over 48 months provides a long-term incentive for the executive to remain with the company and contribute to its sustained growth.

Future Outlook

The stock options are set to vest over 48 equal monthly installments starting April 1, 2025, indicating a long-term incentive structure for the executive.

Industry Context

This is a standard executive compensation event in the biotechnology/pharmaceutical industry, where stock options are commonly used to incentivize and retain key personnel, aligning their performance with the company's long-term success.

Comparison to Industry Standards

• The grant of stock options to a VP-level executive is a common practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen, which frequently use equity incentives to attract and retain top talent.
• The 48-month vesting schedule is a typical industry standard for executive equity grants, designed to encourage long-term commitment and performance.
• The exercise price of $3.20 is tied to the stock's value at the time of grant, a standard approach for non-qualified stock options.

Related Party Transactions

• The grant of stock options to an officer (Peter B. Cancelmo) constitutes a related party transaction, which is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a key executive with shareholders, as the value of the options is tied to the company's stock performance. It could dilute existing shares if options are exercised, but this is a common aspect of equity compensation plans.
• Employees: This transaction is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's approach to executive incentives.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting April 1, 2025.
• The options will remain exercisable until their expiration date of June 30, 2035.

Key Dates

Keywords

Omeros Corp, OMER, Stock Options, Executive Compensation, SEC Form 4, Peter B. Cancelmo, General Counsel, Equity Grant, Vesting Schedule